Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc1300057 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes with revascularisation versus conservative management of participants with 3-vessel coronary artery disease in the ISCHEMIA trial.
EuroIntervention
October 2024
Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.
Background: Whether revascularisation (REV) improves outcomes in patients with three-vessel coronary artery disease (3V-CAD) is uncertain.
Aims: Our objective was to evaluate outcomes with REV (percutaneous coronary intervention [PCI] or coronary artery bypass graft surgery [CABG]) versus medical therapy in patients with 3V-CAD.
Methods: ISCHEMIA participants with 3V-CAD on coronary computed tomography angiography without prior CABG were included.
Restrictive Versus Liberal Transfusion in Patients With Type 1 or Type 2 Myocardial Infarction: A Prespecified Analysis of the MINT Trial.
Circulation
December 2024
St Michael's Hospital, Unity Health Toronto and Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto (S.G.G.).
Background: The MINT trial (Myocardial Ischemia and Transfusion) raised concern for harm from a restrictive versus liberal transfusion strategy in patients with acute myocardial infarction (MI) and anemia. Type 1 and type 2 MI are distinct pathophysiologic entities that may respond differently to blood transfusion. This analysis sought to determine whether the effects of transfusion varied among patients with a type 1 or a type 2 MI and anemia.
View Article and Find Full Text PDFAlirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study.
J Clin Lipidol
August 2024
CPC Clinical Research and Division of Cardiology, University of Colorado School of Medicine, Aurora, CO (Dr Szarek); State University of New York, Downstate Health Sciences University, Brooklyn, NY (Dr Szarek).
Article Synopsis
- - The ODYSSEY OUTCOMES trial evaluated the impact of alirocumab, a drug that targets cholesterol, compared to a placebo on major cardiovascular events in patients with recent acute coronary syndrome, involving over 18,000 participants.
- - Results showed that while both men and women experienced significant reductions in cholesterol levels and cardiovascular events with alirocumab, women had higher initial cholesterol and lipoprotein(a) levels and more co-morbidities.
- - The study concluded that alirocumab improves cardiovascular outcomes post-acute coronary syndrome for both sexes, especially in individuals with higher baseline levels of lipoprotein(a).
Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests.
Circulation
January 2024
Division of Cardiology, University of Colorado School of Medicine, Aurora (M. Szarek, G.G.S.).
Article Synopsis
- - Lipoprotein(a) is known to increase cardiovascular risk and affects how patients benefit from PCSK9 inhibitors like alirocumab, but it's unclear how different testing methods for lipoprotein(a) correlate with cardiovascular events.
- - The ODYSSEY OUTCOMES trial analyzed patients with recent acute coronary syndrome, comparing the risks of major adverse cardiovascular events (MACE) between a placebo group and those treated with alirocumab, based on lipoprotein(a) levels measured by various assays.
- - Among 11,970 participants, different assays showed varying baseline lipoprotein(a) concentrations, with the highest correlation found between certain methods; additional analysis highlighted how lipoprotein(a) levels influenced MACE
Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans.
J Lipid Res
January 2023
Montreal Heart Institute, Montreal, Quebec, Canada; Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada. Electronic address:
The large HDL particles generated by administration of cholesteryl ester transfer protein inhibitors (CETPi) remain poorly characterized, despite their potential importance in the routing of cholesterol to the liver for excretion, which is the last step of the reverse cholesterol transport. Thus, the effects of the CETPi dalcetrapib and anacetrapib on HDL particle composition were studied in rabbits and humans. The association of rabbit HDL to the LDL receptor (LDLr) in vitro was also evaluated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!